Risk-adapted HLA delisting and imlifidase-enabled deceased-donor kidney transplantation in highly sensitized kidney transplant candidates: a German expert consensus report - Takeaways - MDSpire

Risk-adapted HLA delisting and imlifidase-enabled deceased-donor kidney transplantation in highly sensitized kidney transplant candidates: a German expert consensus report

  • By

  • Stefan Reuter

  • Louise Benning

  • Andrea Dick

  • Lisa-Marie Dilz

  • Gunilla Einecke

  • Florian Emmerich

  • Florian Grahammer

  • Rebecca Großmann

  • Wilfried Gwinner

  • Fabian Halleck

  • Michael Hallensleben

  • Falko M. Heinemann

  • Bernd Jänigen

  • Dennis Kannenkeril

  • Teresa Kauke

  • Reinhard Kelsch

  • Stephan Kemmner

  • Malte Andreas Kluger

  • Jan Kowald

  • Andreas Kribben

  • Claudia Lehmann

  • Monika Lindemann

  • Giancarlo Maccagno

  • Christian Morath

  • Anja Mühlfeld

  • Lien Pham

  • Lutz Renders

  • Stefan Schaub

  • Sabine Scherer

  • Christian Seidl

  • Bernd Spriewald

  • Dirk Stippel

  • Julian Stumpf

  • Thuong Hien Tran

  • Rolf Weimer

  • Benjamin Wilde

  • Daniel Zecher

  • Malte Ziemann

  • Svitlana Ziganshyna

  • Nils Lachmann

  • Klemens Budde

  • June 9, 2026

  • 0 min

Share

  • 1

    Kidney transplantation is the preferred treatment for end-stage renal disease, but highly sensitized patients face significant access challenges.

  • 2

    The German expert consensus report provides guidelines for HLA delisting and the use of imlifidase in highly sensitized kidney transplant candidates.

  • 3

    Imlifidase can convert a positive crossmatch into a negative result, enabling transplantation for patients with high HLA antibody levels.

  • 4

    The report emphasizes a risk-adapted approach to candidate selection and post-transplant management for highly sensitized patients.

  • 5

    The acceptable mismatch program aims to improve transplant opportunities for highly sensitized patients, but many remain disadvantaged.

Original Source(s)

Risk-adapted HLA delisting and imlifidase-enabled deceased-donor kidney transplantation in highly sensitized kidney transplant candidates: a German expert consensus report

  • by Stefan Reuter, Louise Benning, Andrea Dick, Lisa-Marie Dilz, Gunilla Einecke, Florian Emmerich, Florian Grahammer, Rebecca Großmann, Wilfried Gwinner, Fabian Halleck, Michael Hallensleben, Falko M. Heinemann, Bernd Jänigen, Dennis Kannenkeril, Teresa Kauke, Reinhard Kelsch, Stephan Kemmner, Malte Andreas Kluger, Jan Kowald, Andreas Kribben, Claudia Lehmann, Monika Lindemann, Giancarlo Maccagno, Christian Morath, Anja Mühlfeld, Lien Pham, Lutz Renders, Stefan Schaub, Sabine Scherer, Christian Seidl, Bernd Spriewald, Dirk Stippel, Julian Stumpf, Thuong Hien Tran, Rolf Weimer, Benjamin Wilde, Daniel Zecher, Malte Ziemann, Svitlana Ziganshyna, Nils Lachmann, Klemens Budde

  • June 9, 2026

Related Content

Analysis of complication management strategies after tympanoplasty under otoendoscopy

Incidence and clinical characterization of retinal detachment in acute retinal necrosis: a global federated database analysis

Development and internal validation of a nomogram for early prediction of hospital-acquired ESKAPE colonization or infection in very preterm infants using indicators available within 24 hours